Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (ACET)
NASDAQ:ACET
ACET Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $2.74
Previous CloseN/A
Volume197.46K
Average Volume (3M)1.16M
Market Cap
$82.40M
Enterprise Value-$53.05M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 12, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,400,960
10 Day Avg. Volume853,084
30 Day Avg. Volume1,157,064
Standard Deviation0.26
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)116.56
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.70
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$7.00Price Target Upside621.65% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Adicet Bio News
PremiumCompany Announcements
Adicet Bio Advances with Phase 1 Trial of ADI-270
PremiumCompany Announcements
Adicet Bio Clears Debts with Banc of California
PremiumCompany Announcements
Adicet Bio Reports Q3 2024 Results and Clinical Progress---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe initiation of Phase 1 trials by Adicet in autoimmune diseases shows progress towards bringing their treatment to market.
Financial StabilityAdicet holds a solid cash position of $202.1 million, providing financial stability for its ongoing and future projects.
Regulatory ApprovalsADI-001 has been granted FDA Fast Track Designation for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement.
Bears Say
Clinical UncertaintyUncertainty surrounding clinical readouts leads to shares being seen as fairly valued.
Market CompetitionGazyva is expected to be used in lupus nephritis patients before Adicet’s CAR T, suggesting Adicet's solution may not be the initial choice in treatment.
Revenue ChallengesAdicet reported no revenues for the quarter, which aligns with expectations but highlights the company's current reliance on development progress rather than sales.
---
Ownership Overview
15.69% Insiders
6.12% Mutual Funds
47.42% Other Institutional Investors
26.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $0.81 and its highest was $2.74 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $82.40M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Mar 12, 2025 which is in 18 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Nov 06, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.341 by $0.001.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -0.36.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,400,960 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.341. Following the earnings report the stock price went up 2.308%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in ACET
---
Adicet Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.00 (621.65% Upside)
$7.00 (621.65% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 21.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 9.5%
Last 30 Days ▼ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.91%
12-Months-Change
Fundamentals
Return on Equity
-58.04%
Trailing 12-Months
Asset Growth
5.45%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
ACET Stock 12 Month Forecast
Average Price Target
$7.00
▲(621.65% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering ACET
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-8.38%
reiterated a buy rating 5 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -8.38% per trade.
---